WuXi AppTec’s 2023 sales largely reliant on the US, report says

WuXi AppTec’s an­nu­al re­port on Mon­day re­veals what’s at stake for the Shang­hai-based ser­vice provider if the BIOSE­CURE bill pass­es, which would re­strict the com­pa­ny from work­ing with US bio­phar­ma com­pa­nies.

As much as 65% of WuXi AppTec’s 2023 rev­enue came from US-based cus­tomers, with the man­u­fac­tur­er fore­cast­ing a sin­gle-dig­it rev­enue in­crease this year “de­spite un­cer­tain­ties in the ex­ter­nal en­vi­ron­ment,” as per the com­pa­ny’s an­nu­al re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.